Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2017, Article ID 2869090, 7 pages
Research Article

The Proline 7 Substitution in the Preproneuropeptide Y Is Associated with Higher Hepatic Lipase Activity In Vivo

1Geriatric Medicine, University of Regensburg, Regensburg, Germany
2Vth Department of Medicine, Mannheim Medical Faculty, Heidelberg University, Mannheim, Germany
3Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University Graz, Graz, Austria
4Synlab Academy, Mannheim, Germany
5Synlab Holding Deutschland GmbH, Augsburg, Germany
6Departments of Internal Medicine, Neurology, Dermatology, Clinic for Endocrinology, Diabetology, and Nephrology, Section of Nephrology, University Leipzig, Leipzig, Germany
7Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg and Centre Hospitalier Emile Mayrisch (CHEM), Esch-sur-Alzette, Luxembourg
8Department of Internal Medicine II, Saarland University Medical Center, Homburg, Saar, Germany

Correspondence should be addressed to Jochen G. Schneider; moc.kooltuo@redienhcs.gj

Received 30 January 2017; Accepted 16 April 2017; Published 30 May 2017

Academic Editor: Darío Acuña-Castroviejo

Copyright © 2017 Stephan Schiekofer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Hepatic lipase (HL) functions as a lipolytic enzyme that hydrolyzes triglycerides and phospholipids present in circulating plasma lipoproteins. Plasma HL activity is known to be regulated by hormonal and metabolic factors, but HL responsiveness to insulin as well as its role in modulating atherosclerotic risk is still controversial. We investigated on the influence of a known polymorphism in the neurotransmitter neuropeptide Y (NPY) on HL activity in two different cohorts consisting of diabetic and nondiabetic patients. HL activity was 24% and 34% higher on nondiabetic and diabetic subjects in the presence of the 7Pro allele in NPY, respectively. The presence of the 7Pro allele was an independent predictor of HL activity in multivariate analyses in both cohorts. These data suggest a regulatory effect of NPY on HL activity. Among carriers of the 7Pro allele, we also found a statistically significant lower absolute number of infarctions compared to noncarriers () and a nonsignificant trend towards less myocardial infarction in the 7Pro allele diabetic carriers (). In conclusion, the common 7Pro allele in NPY was associated with higher HL activity in nondiabetic and diabetic subjects and its presence seems to coincide with a lower frequency of certain cardiovascular events.